Role of Chromium Versus Metformin Supplementations as Adjuvant for Ovulation Induction By Clomiphene Citrate in Infertile Patients With Polycystic Ovary Syndrome : Randomized Controlled Trial
Abstract
Aim: This study aimed to explore the effect of chromium picolinate compared to Metformin supplementation with ovulation induction in polycystic ovary syndrome, In particular, its effect on insulin sensitivity, ovarian response and pregnancy rate. Materials and Methods: This study was conducted as a prospective study, aimed to compare the effect of Chromium and Metformin supplementations on ovulation rate in Polycystic ovary patients undergoing ovulation induction. The present study included 140 women divided into 2 groups each is 70 infertile women diagnosed as polycystic ovary syndrome according to Rotterdam criteria 2017: (oligo-ovulation or anovulation, clinical or biochemical signs of hyperandrogenism, polycystic ovaries on ultrasound). Results: Fasting blood sugar (FBS) and fasting insulin level were significantly decreased in metformin group than in Chromium picolinate group after 3 months of treatment ( p=0.006 ) ( p=0.026 ) respectively. Testosterone significantly decreased in both groups at follow up as compared to basal level ( P-value <0.001, <0.001 respectively with no significant difference between the studied groups regarding testosterone reduction ( P-value=0.416 ) after 3 months of treatment. The two study groups were not significantly different regarding ovulation and pregnancy rates( P-value 0.157, 0.550 ) respectively after 3 months of treatment. The patients who received metformin experienced more side effects compared to those receiving chromium…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 140 participants or records.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.